The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology

William E. Grizzle, O. John Semmes, Joseph Basler, Elzbieta Izbicka, Ziding Feng, Jacob Kagan, Bao Ling Adam, Dean Troyer, Sudhir Srivastava, Mark Thornquist, Zhen Zhang, Ian M. Thompson

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) screening has led to a dramatic increase in prostate cancer detection with a concurrent stage migration. Although the test has revolutionized prostate cancer detection by identifying disease that is potentially curable in the majority of men, only 25% of men receiving test results of PSA >4 ng/ml will have prostate cancer and many men receiving a normal PSA will have disease, including high-grade disease. There is a need for improved biomarkers for detecting prostate cancer. One such method of cancer detection is surface-enhanced laser desorption and ionization (SELDI). The Early Detection Research Network (EDRN) validation study for SELDI for prostate cancer is described. In a three-stage study, the portability and reproducibility of the technique will be determined; the predictive algorithm will be refined in a multi-institutional case-control population; followed by ultimate validation in the context of a prospective trial with complete disease ascertainment. The unique aspect of the EDRN SELDI validation study is the novel use of two groups of cancer cases: those cases with higher-risk disease (Gleason ≥ 7) and those cases with lower-risk disease (Gleason ≤ 6). This study will allow the first evaluation of a predictive algorithm that includes prognosis in disease screening. The EDRN SELDI prostate cancer biomarker validation study is a rigorous evaluation of a new detection method for prostate cancer. The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease.

Original languageEnglish (US)
Pages (from-to)337-343
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume22
Issue number4
DOIs
StatePublished - Jul 2004

Fingerprint

Prostatic Neoplasms
Lasers
Biomarkers
Research
Validation Studies
Prostate-Specific Antigen
Tumor Biomarkers
Neoplasms
Population

Keywords

  • Biomarkers
  • Cancer detection
  • Prostate cancer
  • Proteomics
  • SELDI

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study : A study in biomarker validation in genitourinary oncology. / Grizzle, William E.; Semmes, O. John; Basler, Joseph; Izbicka, Elzbieta; Feng, Ziding; Kagan, Jacob; Adam, Bao Ling; Troyer, Dean; Srivastava, Sudhir; Thornquist, Mark; Zhang, Zhen; Thompson, Ian M.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 22, No. 4, 07.2004, p. 337-343.

Research output: Contribution to journalArticle

Grizzle, William E. ; Semmes, O. John ; Basler, Joseph ; Izbicka, Elzbieta ; Feng, Ziding ; Kagan, Jacob ; Adam, Bao Ling ; Troyer, Dean ; Srivastava, Sudhir ; Thornquist, Mark ; Zhang, Zhen ; Thompson, Ian M. / The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study : A study in biomarker validation in genitourinary oncology. In: Urologic Oncology: Seminars and Original Investigations. 2004 ; Vol. 22, No. 4. pp. 337-343.
@article{47c0b78df90f4e04a3abee765664a402,
title = "The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology",
abstract = "Prostate-specific antigen (PSA) screening has led to a dramatic increase in prostate cancer detection with a concurrent stage migration. Although the test has revolutionized prostate cancer detection by identifying disease that is potentially curable in the majority of men, only 25{\%} of men receiving test results of PSA >4 ng/ml will have prostate cancer and many men receiving a normal PSA will have disease, including high-grade disease. There is a need for improved biomarkers for detecting prostate cancer. One such method of cancer detection is surface-enhanced laser desorption and ionization (SELDI). The Early Detection Research Network (EDRN) validation study for SELDI for prostate cancer is described. In a three-stage study, the portability and reproducibility of the technique will be determined; the predictive algorithm will be refined in a multi-institutional case-control population; followed by ultimate validation in the context of a prospective trial with complete disease ascertainment. The unique aspect of the EDRN SELDI validation study is the novel use of two groups of cancer cases: those cases with higher-risk disease (Gleason ≥ 7) and those cases with lower-risk disease (Gleason ≤ 6). This study will allow the first evaluation of a predictive algorithm that includes prognosis in disease screening. The EDRN SELDI prostate cancer biomarker validation study is a rigorous evaluation of a new detection method for prostate cancer. The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease.",
keywords = "Biomarkers, Cancer detection, Prostate cancer, Proteomics, SELDI",
author = "Grizzle, {William E.} and Semmes, {O. John} and Joseph Basler and Elzbieta Izbicka and Ziding Feng and Jacob Kagan and Adam, {Bao Ling} and Dean Troyer and Sudhir Srivastava and Mark Thornquist and Zhen Zhang and Thompson, {Ian M.}",
year = "2004",
month = "7",
doi = "10.1016/j.urolonc.2004.04.008",
language = "English (US)",
volume = "22",
pages = "337--343",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study

T2 - A study in biomarker validation in genitourinary oncology

AU - Grizzle, William E.

AU - Semmes, O. John

AU - Basler, Joseph

AU - Izbicka, Elzbieta

AU - Feng, Ziding

AU - Kagan, Jacob

AU - Adam, Bao Ling

AU - Troyer, Dean

AU - Srivastava, Sudhir

AU - Thornquist, Mark

AU - Zhang, Zhen

AU - Thompson, Ian M.

PY - 2004/7

Y1 - 2004/7

N2 - Prostate-specific antigen (PSA) screening has led to a dramatic increase in prostate cancer detection with a concurrent stage migration. Although the test has revolutionized prostate cancer detection by identifying disease that is potentially curable in the majority of men, only 25% of men receiving test results of PSA >4 ng/ml will have prostate cancer and many men receiving a normal PSA will have disease, including high-grade disease. There is a need for improved biomarkers for detecting prostate cancer. One such method of cancer detection is surface-enhanced laser desorption and ionization (SELDI). The Early Detection Research Network (EDRN) validation study for SELDI for prostate cancer is described. In a three-stage study, the portability and reproducibility of the technique will be determined; the predictive algorithm will be refined in a multi-institutional case-control population; followed by ultimate validation in the context of a prospective trial with complete disease ascertainment. The unique aspect of the EDRN SELDI validation study is the novel use of two groups of cancer cases: those cases with higher-risk disease (Gleason ≥ 7) and those cases with lower-risk disease (Gleason ≤ 6). This study will allow the first evaluation of a predictive algorithm that includes prognosis in disease screening. The EDRN SELDI prostate cancer biomarker validation study is a rigorous evaluation of a new detection method for prostate cancer. The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease.

AB - Prostate-specific antigen (PSA) screening has led to a dramatic increase in prostate cancer detection with a concurrent stage migration. Although the test has revolutionized prostate cancer detection by identifying disease that is potentially curable in the majority of men, only 25% of men receiving test results of PSA >4 ng/ml will have prostate cancer and many men receiving a normal PSA will have disease, including high-grade disease. There is a need for improved biomarkers for detecting prostate cancer. One such method of cancer detection is surface-enhanced laser desorption and ionization (SELDI). The Early Detection Research Network (EDRN) validation study for SELDI for prostate cancer is described. In a three-stage study, the portability and reproducibility of the technique will be determined; the predictive algorithm will be refined in a multi-institutional case-control population; followed by ultimate validation in the context of a prospective trial with complete disease ascertainment. The unique aspect of the EDRN SELDI validation study is the novel use of two groups of cancer cases: those cases with higher-risk disease (Gleason ≥ 7) and those cases with lower-risk disease (Gleason ≤ 6). This study will allow the first evaluation of a predictive algorithm that includes prognosis in disease screening. The EDRN SELDI prostate cancer biomarker validation study is a rigorous evaluation of a new detection method for prostate cancer. The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease.

KW - Biomarkers

KW - Cancer detection

KW - Prostate cancer

KW - Proteomics

KW - SELDI

UR - http://www.scopus.com/inward/record.url?scp=3343026530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3343026530&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2004.04.008

DO - 10.1016/j.urolonc.2004.04.008

M3 - Article

C2 - 15283893

AN - SCOPUS:3343026530

VL - 22

SP - 337

EP - 343

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -